

**Government of the District of Columbia
Department of Health**

**Prescription Drug Monitoring Program
Advisory Committee Meeting**

**899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002**

January 15th, 2019

10:00am- 12:00 pm

OPEN SESSION MINUTES

Open Session Minutes

Quorum: Yes

Introduction:		
1023-O-01	<p><u>Welcome & Introductions</u></p> <p><u>Charge of the Committee</u></p> <p>The Committee shall convene at least two (2) times per year to advise the Director:</p> <ul style="list-style-type: none">(a) On the implementation and evaluation of the Program;(b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances;(c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;(d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;(e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and(f) Regarding the design and implementation of educational courses for:<ul style="list-style-type: none">(1) Persons who are authorized to access the prescription monitoring information;(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program;(3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and(4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program.	

1023-O-02	<p><u>Approval of October 2018 PDMP Advisory Committee Meeting Minutes</u></p> <p>Motion to approve the October meeting minutes by: Jacqueline Watson Seconded by: John Haines Motion carries, minutes approved</p>	
1023 -O-03	<p><u>2018 PDMP Advisory Committee Year in Review Summary</u></p> <p>Dr. Shauna White presented a draft of the 2018 Prescription Drug Monitoring Program Advisory Committee Year in Review Summary, which will be submitted to the Director of DC Health.</p> <p>The summary will include recommendations made to the Director of DC Health, pending legislation, DC PDMP Best Practice Checklist progress update, current and future outreach activities.</p> <p>The District of Columbia Prescription Drug Monitoring Program Advisory Committee Meeting held four meetings on the following dates in 2018:</p> <ul style="list-style-type: none"> • January 17th 2018 • April 11th 2018 • July 17th 2018 • October 23rd 2018 <p>The Committee made several recommendations to the Director of DC Health. These recommendations included the addition of Gabapentin to the regulations as a drug of concern.</p> <p>Additionally, the Committee had robust discussions regarding Naloxone and at the recommendation of the attorney advisor, that DC Health should find a method to capture Naloxone dispensation data outside of the PDMP.</p> <p>The Committee was informed about the ongoing Center for Disease Control (CDC) grants which include:</p> <p><i>Prescription Drug Overdose Data Driven Prevention Initiative (DDPI)</i> grant that funds the opioid awareness communications campaign.</p> <p><i>Cooperative Agreement for Emergency Response: Public Health Crisis Response (COAP or Crisis)</i> grant which funds the PDMP Statewide Integration where DC PDMP data will be integrated into the workflow</p>	

	<p>of pharmacy dispensing systems (PDS), electronic health records (EHR) and health information exchanges (HIE). This will ease the burden of providers signing into multiple systems.</p> <p>The Committee provided feedback and revised the PDMP best practice checklist based on a model from the Prescription Drug Monitoring Program (PDMP) Training and Technical Assistance Center (TTAC). The Program was able to set timelines, monitor and evaluate progress.</p> <p>Program staff have participated in the opioid strategic planning groups which included agencies within DC government and stakeholders from outside of DC government such as the DC Hospital Association.</p> <p>Sheri Doyle asked about the goals of the COAP grant and the PDMP Advisory Committee. Dr. Shauna White explained that the COAP grant provides funding for activities that were not allowable in the DDPI grant and the Enhanced State Opioid Overdose Surveillance (ESOOS) grant and reviewed the charge of the PDMP Advisory Committee.</p> <p>Discussion among committee members regarding format and content of the final version of the 2018 PDMP Advisory Committee Year in Review Summary.</p> <p>Discussion among committee members regarding submitting supporting data to reintroduce a recommendation for mandatory query to the DC Health Director.</p> <p>Frank Meyers requested that the program provide data on queries by prescribers to establish whether registration equals use or not.</p> <p>Dr. White stated that we should also look at the number of opioid and controlled substance prescriptions written by prescribers.</p> <p>Dr. Watson stated that we need to encourage users to check the DC PDMP and not necessarily CRISP as the DC PDMP provides more timely prescription data. Dr. Kirilichin stated that prescribers may be checking CRISP as it already integrated into electronic health records (EHR) and health information exchanges (HIE) within some District hospitals.</p> <p>Sheri Doyle stated that Wisconsin does not have mandatory query but they do have high utilization rates due to effective PDMP integration into EHRs.</p>	
<p>1023 -O-04</p>	<p><u>DC Opioid Strategic Plan (Live. Long. DC)</u></p>	

	<p>Dr. Watson discussed the District’s Opioid Strategic Plan (Live. Long. DC) that the Mayor released in December 2018. The strategic plan is the strategy that the District has in place to reduce opioid misuse and abuse.</p> <p>DC Health Director, Dr. Nesbitt is the co-chair of the opioid working group and the strategic planning committee. Dr. Nesbitt is currently serving in dual roles as the Director of DC Health and the Interim Director of the Department of Behavioral Health.</p> <p>Dr. Watson stated that the opioid crisis in DC is different in comparison to other states. Dr. Watson addressed the recent media coverage in the Washington Post regarding the District’s response to the opioid epidemic and alleged that not enough is being done to address those most impacted by the epidemic in DC. There will be a hearing on January 28th 2019, requested by Council Member, Charles Allen where the Director will testify on behalf of DBH on how the District is responding the opioid epidemic.</p>	
<p>1023 -O-05</p>	<p><u>Report from Attorney Advisory</u> (a) PDMP Legislative Update</p> <p>Require the mandatory registration of prescribers and dispensers, including new licensees, by March, 2019.</p> <p>The PDMP legislation was initially drafted as emergency legislation. There is a temporary and permanent bill when emergency legislation is moved. The committee’s goal was to have mandatory registration for physicians’ by the end of 2018 renewal cycle. Council was unable to pass legislation to meet that deadline.</p> <p>Council extended the date to March 31st, 2019 and dropped the emergency and temporary bill and only moved the permanent bill for all eligible prescribers. The legislation is currently going through the mayoral review then the 30 day congressional review. DC Health will develop an implementation plan for providers to come into compliance until the new law.</p> <p>Dr. Watson discussed communicating with prescribers ahead of the mandate. Carla Williams stated that as counsel for the Board of Dentistry she has reminded the associations that the mandate is coming and encourages them to register ahead of time. Professional licenses</p>	

will not be issued or renewed without registration after the mandate is in place.

Dr. Watson and Frank Meyers stated that as physicians have completed the renewal process enforcement of mandatory registration will be heavily reliant on program staff. Frank Meyers has expressed concern over the March 2019 deadline. Dr. Watson stated that in light of the current environment we must be aggressive in putting a plan in place to have all providers compliant.

Frank Meyers suggested that perhaps the program could automatically enroll physicians and send users their credentials. He stated that enforcement by the Board of Medicine would be difficult as there are already logistical issues with disciplinary actions from the audits. Discussion among committee members regarding auto enrollment logistics. Carla Williams stated that there is no legal reason why the program could not automatically enroll users.

Committee members discussed current communication and marketing strategies. Dr. Watson stated that marketing efforts must be streamlined and coordinated between the program and DC Health communications around opioid use/misuse.

Carla Williams also discussed the following highlights from the new legislation:

- Prohibit Health Occupations Boards from licensing, renewing, reactivating, or reinstating a licensee, that is required to be registered, without proof that the licensee has registered with the PDMP.
- Allow the FBI to obtain reports related to drug investigations.

(b) Update: Gabapentin to be added as drug of concern

Currently under review in the Mayor's office. There is legal sufficiency. There were questions from the Deputy Mayor's Office regarding why the Program wanted to add Gabapentin as a drug of concern. Program staff did put together sufficient information to support this addition to the PDMP regulations.

1023 -O-06

Program Updates

(a) Program Statistics

Dr. White presented the PDMP Program Statistics. Registration for physicians increased after the physician renewal period by 687 users. Registration for pharmacists and pharmacy technicians are expected to increase as these roles are currently in a renewal cycle. A link will be provided to register for the PDMP during the renewal process.

An increase in registration is also expected after the pending mandatory registration legislation passes and the Statewide Gateway Integration project commences.

User Role	# of Registered Users January 2019
Physician (MD, DO)	1,606
Medical Resident	61
Physician Assistant	139
Pharmacist	514
Nurse Practitioner	251
Dentist	94
*Pharmacy Technician (Delegate)	7
Veterinarian	33
Podiatrist	10
VA Prescriber	25
Other(Licensing Board Investigators, Law Enforcement, Medical Examiner)	23
TOTAL	2,763

(b) Past and Future Outreach Activities

Dr. White discussed past and present outreach activities and the value of on-site registration. Dr. Shauna White discussed leveraging the current relationships with DC Healthcare Finance, DC Primary Care Association, and DC Medical Society.

Dr. Watson stated that Program should revisit the licensing boards and provide updated information on upcoming mandates, and share the DC opioid strategic plan.

Dr. Kirilichin discussed partnerships with GW MFA and revisiting United Medical Center as Wards 7-8 have been disproportionately affected by the opioid epidemic and this is the District's most vulnerable population. Recommendations were made to target Federally Qualified Health Centers (FQHCs), community clinics and the Mary's Center. This should be a part of a thirty day outreach strategy.

Sheri Doyle asked whether we could tie PDMP registration to continuing education (CE) or continuing medical education (CME) events. Frank Meyers stated that this would be possible as part of the event alongside the Live.Long.DC. strategic plan.

Dr. Kirilichin stated that data waiver and buprenorphine training events would be a strategic way to increase registration.

(c) PDMP Annual Report

Dr. White discussed the draft annual report that would be available to the public. She recommends DC do a report similar to Virginia's report.

(d) PDMP Best Practice Checklist updates and discussion

Dr. White presented the updated PDMP Best Practice Checklist derived from PDMP TTAC.

Discussion regarding prescriber reports cards and encouraging prescribers' login to the DC PDMP to access their report. Sheri Doyle will share PDMP TTAC best practice for prescriber reports. Sheri Doyle inquired whether the DC PDMP is currently engaged in active academic detailing. Dr. Shauna White shared that the program is not however it is a tool that can be used in the future.

Dr. Watson inquired about when planned activities listed will be put into action. Dr. White shared that the current focus is the statewide gateway integration, the professional license integration and outreach.

0115-O-07

Grant Updates

(a) Statewide Gateway Integration

Dr. Justin Ortique provided a brief overview of the Statewide Gateway Integration that will integrate DC PDMP data into electronic health records, health information exchanges and pharmacy dispensing systems through CDC grant funding. A press release has been drafted and a website has been created for healthcare entities to register for integration. Currently, the program is working with DC Health communications' to coordinate efforts with the Mayor's Office.

Discussion regarding continuing integration after grant funding ends and which hospitals would be affected. Dr. Ortique stated that there are

other grant funded opportunities the District could apply for to continue funding the integration.

Dr. Kirilichin stated that hospital systems like GW MFA and MedStar have recently invested into integrating CRISP into its EHRs. Dr. Kirilichin asked about outreach to Kaiser. There is no current outreach to Kaiser therefore, the program will include Kaiser in its future outreach activities.

(b) Professional License Integration

Dr. White provided an overview of the ongoing professional license integration project. The DC PDMP vendor Appriss will integrate DC professional licensing information so that users whose credentials match will be automatically approved into the system. Currently, this credentialing is done manually.

(c) Opioid Indicator Dashboard

Dr. White provided an overview of upcoming opioid indicator dashboard. This will be accomplished through a collaboration with DC Health, Office of the Chief Medical Examiner, Fire and Emergency Medical Services and Department of Forensic Sciences.

The dashboard will include opioid overdose data, opioid related transports and overdose death data. The dashboard should be completed by summer 2019.

Dr. Kirilichin suggested that next steps include user specific data dashboards and offered to provide information on a physician specific dashboard from Texas.

(d) Opioid Awareness Communications Campaign

Olamide Iyanda provided an update of the re-launch of the opioid awareness communications campaign that will run until May 14th 2019. The campaign will consist of metro trains, buses and mobile geo-tagging. The buses will depart from Southern, Northern and Bladensburg bus garages targeting wards 5, 7, and 8.

Commander John Haines gave MPDs perspective on the hotspots in the areas on Georgia Avenue, Benning Road, and Division Avenue,

	<p>Washington Highlands from MPDs perspective, using hotspot data from the opioid response groups.</p> <p>Dr. Watson stated that the communications campaign material provided from the CDC does not represent the District’s population. Dr. Watson stated that we must use the DC data and information to drive discussions about the campaign material and work with CDC to amend the materials.</p> <p>Dr. Kirilichin suggested that we work with communities with similar populations such as Baltimore that have launched a successful communications' campaign.</p> <p>Discussion on process to launch communications campaign with CDC. Dr. Watson would like to set up a call with CDC to revise the campaign.</p>	
<p>0115-O-08 Matters for Consideration</p>	<p><u>Action Items</u></p> <p>Future meeting dates:</p> <ul style="list-style-type: none"> • Meeting date has been changed to Tuesday April 30th 2019. • July 16th, 2019 • October 15th, 2019 	
<p>0115-O-09</p>	<p>Other news/highlights from Committee members</p> <p>Commander John Haines discussed a joint taskforce with MPD, ATF, FBI where over 46 kilos of heroin laced fentanyl were seized. Data from the Medical Examiner’s Office reveals that the majority of overdose deaths contain traces of fentanyl.</p> <p>Currently, an accidental overdose death is classed as a natural death and there is no further investigation done. By February 1st, an investigation of those death will be done to trace drugs back to the dealer. MPD has commitments from the US Attorney’s Office and Federal Courts to prosecute dealers.</p> <p>Dr. Kirilichin offered to provide assistance from medical students who could assist with PDMP initiatives and opioid related issues in the District.</p> <p>Frank Myers agreed with Dr. Kirilichin and stated that he welcomes any student to assist him with the Board of Medicine.</p> <p>Dr. Watson also agreed that having medical students would be a great opportunity for both DC Health and the student. Dr. Watson suggested that both Frank Myers and Dr. White would benefit from working with the students.</p>	

	Sheri Doyle shared a resource from Pew Charitable Trust titled, “ <i>When Are Prescribers Required to Use Prescription Drug Monitoring Programs?</i> ”	
Comments from the Public	None	
Motion to Adjourn the Open Session	<p>Madam Chair, I move that the Committee close the Open Public session portion of the meeting.</p> <p>Motion -Dr. Jacqueline Watson Seconded by: Commander John Haines Motion carried.</p> <p style="text-align: center;">(Roll Call Vote)</p>	
Action Steps	<ul style="list-style-type: none"> • Outreach to DC Health licensing boards • 2018 Prescription Drug Monitoring Program Year in Review Summary • Opioid Awareness Communications Campaign <p>Future meeting dates:</p> <ul style="list-style-type: none"> • April 30th, 2019. • July 16th, 2019 • October 15th, 2019 	

This concludes the Public Open Session of the meeting.
Open Session Meeting Adjourned at 11:58 AM